The emerging potential of Aptamers as therapeutic agents in infection and inflammation.
Pharmacol Ther
; 238: 108173, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-1886025
ABSTRACT
Refined from pools of random sequence oligonucleotides, nucleic acid aptamers have been found to bind an almost limitless array of targets, including clinically-relevant proteins. Comparable to their antibody counterparts, aptamers display significant advantages over protein-based therapeutics in part due to their flexibility in chemical modifications, small size, and scalability. Despite the perceived benefits, and amidst the growth of an increasing number of clinically approved nucleic acid-based therapeutics, orthodox biologics remain dominant. Research over the last three decades has identified several aptamers that contain the potential to reshape the medicinal field as both diagnostic tools and treatments. Herein, we provide a tailored overview of promising developments in therapeutic nucleic acid-based aptamers in the treatment of infection and inflammation and their proposed future applications.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biological Products
/
Nucleic Acids
/
Aptamers, Nucleotide
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Pharmacol Ther
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS